Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management
Tóm tắt
Từ khóa
Tài liệu tham khảo
Reiner, 2011, ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), Eur Heart J, 32, 1769, 10.1093/eurheartj/ehr158
Heart Protection Study Collaborative Group, 2002, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial, Lancet, 360, 7, 10.1016/S0140-6736(02)09327-3
Ridker, 2008, Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein, N Engl J Med, 359, 2195, 10.1056/NEJMoa0807646
Kashani, 2006, Risks associated with statin therapy: a systematic overview of randomized clinical trials, Circulation, 114, 2788, 10.1161/CIRCULATIONAHA.106.624890
Heart Outcomes Prevention Evaluation Study Investigators, 2000, Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy, Lancet, 355, 253, 10.1016/S0140-6736(99)12323-7
Dahlöf, 2002, Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol, Lancet, 359, 995, 10.1016/S0140-6736(02)08089-3
Carter, 2013, Risk of incident diabetes among patients treated with statins: population based study, BMJ, 346, 2610, 10.1136/bmj.f2610
Mancini, 2013, Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update, Can J Cardiol, 29, 1553, 10.1016/j.cjca.2013.09.023
Richardson, 2013, Statins and cognitive function: a systematic review, Ann Intern Med, 159, 688, 10.7326/0003-4819-159-10-201311190-00007
Bruckert, 2005, Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study, Cardiovasc Drugs Ther, 19, 403, 10.1007/s10557-005-5686-z
Buettner, 2012, Statin use and musculoskeletal pain among adults with and without arthritis, Am J Med, 125, 176, 10.1016/j.amjmed.2011.08.007
Cohen, 2012, Understanding statin use in America and gaps in patient education (USAGE): an internet-based survey of 10,138 current and former statin users, J Clin Lipidol, 6, 208, 10.1016/j.jacl.2012.03.003
Zhang, 2013, Discontinuation of statins in routine care settings: a cohort study, Ann Int Med, 158, 526, 10.7326/0003-4819-158-7-201304020-00004
El-Salem, 2011, Prevalence and risk factors of muscle complications secondary to statins, Muscle Nerve, 44, 877, 10.1002/mus.22205
Chodick, 2008, Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel, Clin Ther, 30, 2167, 10.1016/j.clinthera.2008.11.012
Jackevicius, 2002, Adherence with statin therapy in elderly patients with and without acute coronary syndromes, JAMA, 288, 462, 10.1001/jama.288.4.462
Chowdhury, 2013, Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences, Eur Heart J, 34, 2940, 10.1093/eurheartj/eht295
Rosenson, 2014, An assessment by the statin muscle safety task force: 2014 update, J Clin Lipidol, 8, 558, 10.1016/j.jacl.2014.03.004
Ganga, 2014, A systematic review of statin-induced muscle problems in clinical trials, Am Heart J, 168, 6, 10.1016/j.ahj.2014.03.019
Finegold, 2014, What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice, Eur J Prev Cardiol, 21, 464, 10.1177/2047487314525531
Parker, 2013, Effect of statins on skeletal muscle function, Circulation, 127, 96, 10.1161/CIRCULATIONAHA.112.136101
Keech, 1994, Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study, Eur Heart J, 15, 255, 10.1093/oxfordjournals.eurheartj.a060485
MRC/BHF Heart Protection Study Collaborative Group, 2009, Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people, BMC Clin Pharmacol, 9, 6, 10.1186/1472-6904-9-6
Mampuya, 2013, Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience, Am Heart J, 166, 597, 10.1016/j.ahj.2013.06.004
Nielsen, 2012, Statin use and reduced cancer-related mortality, N Engl J Med, 367, 1792, 10.1056/NEJMoa1201735
Nielsen, 2014, Statin use before diabetes and risk of microvascular disease: a nationwide nested matched study, Lancet Diabet Endocrinol, 2, 894, 10.1016/S2213-8587(14)70173-1
Pasternak, 2002, ACC/AHA/NHLBI Clinical advisory on the use and safety of statins, Circulation, 106, 1024, 10.1161/01.CIR.0000032466.44170.44
Downs, 2001, Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Additional perspectives on tolerability of long-term treatment with lovastatin, Am J Cardiol, 87, 1074, 10.1016/S0002-9149(01)01464-3
Armitage, 2007, The safety of statins in clinical practice, Lancet, 370, 1781, 10.1016/S0140-6736(07)60716-8
Joy, 2009, Narrative review: statin-related myopathy, Ann Intern Med, 150, 858, 10.7326/0003-4819-150-12-200906160-00009
Corsini, 2003, The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk, Cardiovasc Drugs Ther, 17, 265, 10.1023/A:1026132412074
Armitage, 2014, Misrepresentation of statin safety evidence, Lancet, 384, 1263, 10.1016/S0140-6736(14)61765-7
Alfirevic, 2014, Phenotype standardization for statin-induced myotoxicity, Clin Pharmacol Ther, 96, 470, 10.1038/clpt.2014.121
Keating, 2013, Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy, Ann Pharmacother, 47, 398, 10.1345/aph.1R509
Athyros, 2008, Effectiveness of ezetimibe alone or in combination with twice a week atorvastatin (10 mg) for statin intolerant high-risk patients, Am J Cardiol, 101, 483, 10.1016/j.amjcard.2007.09.096
Reddy, 2009, Efficacy of combination drug pulse therapy in maintaining lipid levels in patients intolerant of daily statin use, J Clin Hypertens (Greenwich), 11, 766, 10.1111/j.1559-4572.2009.00055.x
Norata, 2013, New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs, Eur Heart J, 34, 1783, 10.1093/eurheartj/eht088
Cannon, IMProved Reduction of Outcomes: Vytorin Efficacy International Trial. A multicenter, double-blind, randomized study to establish the clinical benefit and safety of Vytorin (ezetimibe/simvastatin tablet) vs simvastatin monotherapy in high-risk subjects presenting with acute coronary syndrome
Stein, 2008, Efficacy and tolerability of Fluvastatin XL 80 mg alone, ezetimibe alone and the combination of Fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins: a randomized, double-blind, double-dummy trial, Am J Cardiol, 101, 490, 10.1016/j.amjcard.2007.09.099
Davidson, 1999, Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects, Arch Intern Med, 159, 1893, 10.1001/archinte.159.16.1893
Heel, 1980, Colestipol: a review of its pharmacological properties and therapeutic efficacy in patients with hypercholesterolaemia, Drugs, 19, 161, 10.2165/00003495-198019030-00001
Knopp, 1987, Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia, Am J Med, 83, 50, 10.1016/0002-9343(87)90871-0
ACCORD Study Group, 2010, Effects of combination lipid therapy in type 2 diabetes mellitus, N Engl J Med, 362, 1563, 10.1056/NEJMoa1001282
Keech, 2005, Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial, Lancet, 366, 1849, 10.1016/S0140-6736(05)67667-2
Guo, 2012, Meta-analysis of safety of the coadministration of statin with fenofibrate in patients with combined hyperlipidemia, Am J Cardiol, 110, 1296, 10.1016/j.amjcard.2012.06.050
Capuzzi, 1998, Efficacy and safety of an extended-release niacin (Niaspan): a long-term study, Am J Cardiol, 82, 74U, 10.1016/S0002-9149(98)00731-0
AIM-HIGH Investigators, 2011, Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy, N Engl J Med, 365, 2255, 10.1056/NEJMoa1107579
HPS2-THRIVE Collaborative Group, 2013, HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment, Eur Heart J, 34, 1279, 10.1093/eurheartj/eht055
Anderson, 2000, Long term cholesterol-lowering effects of psyllium as an adjunct to diet therapy in the treatment of hypercholesterolemia, Am J Clin Nutr, 71, 1433, 10.1093/ajcn/71.6.1433
Gylling, 2014, Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease, Atherosclerosis, 232, 346, 10.1016/j.atherosclerosis.2013.11.043
Jenkins, 2011, Effect of a dietary portfolio of cholesterol-lowering foods given at 2 levels of intensity of dietary advice on serum lipids in hyperlipidemia: a randomized controlled trial, JAMA, 306, 831, 10.1001/jama.2011.1202
Taylor, 2015, A randomized trial of Coenzyme Q10 in patients with confirmed statin myopathy, Atherosclerosis, 238, 329, 10.1016/j.atherosclerosis.2014.12.016
Banach, 2015, Effects of Coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials, Mayo Clinic Proc, 90, 24, 10.1016/j.mayocp.2014.08.021
Bookstaver, 2012, Effect of Coenzyme Q10 supplementation on statin-induced myalgias, Am J Cardiol, 110, 526, 10.1016/j.amjcard.2012.04.026
Caso, 2007, Effect of Coenzyme Q10 on myopathic symptoms in patients treated with statins, Am J Cardiol, 99, 1409, 10.1016/j.amjcard.2006.12.063
Michalska-Kasiczak, 2014, Analysis of vitamin D levels in patients with and without statin-associated myalgia – a systematic review and meta-analysis of 7 studies with 2420 patients, Int J Cardiol, 178C, 111
Mannarino, 2014, Nutraceuticals for the treatment of hypercholesterolemia, Eur J Intern Med, 25, 592, 10.1016/j.ejim.2014.06.008
Li, 2014, A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia, PLoS One, 9, e98611, 10.1371/journal.pone.0098611
Lambert, 2012, The PCSK9 decade: thematic review series: new lipid and lipoprotein targets for the treatment of cardiometabolic diseases, J Lipid Res, 53, 2515, 10.1194/jlr.R026658
Stein, 2014, Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9, Annu Rev Med, 65, 417, 10.1146/annurev-med-022613-090402
Norata, 2014, Targeting PCSK9 for hypercholesterolemia, Annu Rev Pharmacol Toxicol, 54, 273, 10.1146/annurev-pharmtox-011613-140025
Stroes, 2014, Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab, J Am Coll Cardiol, 63, 2541, 10.1016/j.jacc.2014.03.019
Sullivan, 2012, Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial, JAMA, 308, 2497, 10.1001/jama.2012.25790
Moriarty, ODYSSEY ALTERNATIVE: efficacy and safety of alirocumab versus ezetimibe, in patients with statin intolerance as defined by a placebo run-in and statin rechallenge arm
Stein, 2014, Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in 4 Phase 2 trials, Eur Heart J, 35, 2249, 10.1093/eurheartj/ehu085
Tavori, 2014, Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction, Expert Rev Cardiovasc Ther, 12, 1137, 10.1586/14779072.2014.954551
ClinicalTrials.gov, Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER)
ClinicalTrials.gov, ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727)
ClinicalTrials.gov, The Evaluation of Bococizumab (PF-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects (SPIRE-1)
ClinicalTrials.gov, The Evaluation of Bococizumab (PF-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects (SPIRE-2)
Davidson, 2013, Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib, J Lipid Res, 54, 467, 10.1194/jlr.M032615
Nicholls, 2011, Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial, JAMA, 306, 2099, 10.1001/jama.2011.1649
ClinicalTrials.gov, REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification
ClinicalTrials.gov, A Study of Evacetrapib in High-Risk Vascular Disease (ACCELERATE)
Needham, 2014, Statin myotoxicity: a review of genetic susceptibility factors, Neuromuscul Disord, 24, 4, 10.1016/j.nmd.2013.09.011
Phillips, 2002, Statin-associated myopathy with normal creatine kinase levels, Ann Intern Med, 137, 581, 10.7326/0003-4819-137-7-200210010-00009
Mohaupt, 2009, Association between statin-associated myopathy and skeletal muscle damage, CMAJ, 181, E11, 10.1503/cmaj.081785
Lamperti, 2005, Muscle coenzyme Q10 level in statin-related myopathy, Arch Neurol, 62, 1709, 10.1001/archneur.62.11.1709
Schick, 2007, Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin, Clin Pharmacol Ther, 81, 650, 10.1038/sj.clpt.6100124
Stringer, 2013, Decreased skeletal muscle mitochondrial DNA in patients with statin-induced myopathy, J Neurol Sci, 325, 142, 10.1016/j.jns.2012.12.023
Laaksonen, 1996, The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle, Am J Cardiol, 77, 851, 10.1016/S0002-9149(97)89180-1
Päivä, 2005, High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial, Clin Pharmacol Ther, 78, 60, 10.1016/j.clpt.2005.03.006
Wu, 2011, Evaluation of skeletal muscle during calf exercise by 31-phosphorus magnetic resonance spectroscopy in patients on statin medications, Muscle Nerve, 43, 76, 10.1002/mus.21847
Marcoff, 2007, The role of coenzyme Q10 in statin-associated myopathy: a systematic review, J Am Coll Cardiol, 49, 2231, 10.1016/j.jacc.2007.02.049
Hanai, 2007, The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity, J Clin Invest, 117, 3940
Mallinson, 2009, Blunted Akt/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy, J Physiol, 587, 219, 10.1113/jphysiol.2008.164699
Mallinson, 2012, Pharmacological activation of the pyruvate dehydrogenase complex reduces statin-mediated upregulation of FOXO gene targets and protects against statin myopathy in rodents, J Physiol, 590, 6389, 10.1113/jphysiol.2012.238022
Araki, 2012, Hydrophobic statins induce autophagy and cell death in human rhabdomyosarcoma cells by depleting geranylgeranyl diphosphate, Eur J Pharmacol, 674, 95, 10.1016/j.ejphar.2011.10.044
Ghatak, 2010, The genetics of statin-induced myopathy, Atherosclerosis, 210, 337, 10.1016/j.atherosclerosis.2009.11.033
Curran, 2014, Nitric oxide-dependent activation of CaMKII increases diastolic sarcoplasmic reticulum calcium release in cardiac myocytes in response to adrenergic stimulation, PLoS One, 9, e87495, 10.1371/journal.pone.0087495
Crane, 2001, Biochemical functions of coenzyme Q10, J Am Coll Nutr, 20, 591, 10.1080/07315724.2001.10719063
Vladutiu, 2006, Genetic risk factors associated with lipid-lowering drug-induced myopathies, Muscle Nerve, 34, 153, 10.1002/mus.20567
Szendroedi, 2011, The role of mitochondria in insulin resistance and type 2 diabetes mellitus, Nat Rev Endocrinol, 8, 92, 10.1038/nrendo.2011.138
Szendroedi, 2007, Insulin-stimulated mitochondrial ATP synthesis occurs independently of intramyocellular lipid accumulation in well-controlled type 2 diabetic humans, PLoS Med, 4, e154, 10.1371/journal.pmed.0040154
Mikus, 2013, Simvastatin impairs exercise training adaptations, J Am Coll Cardiol, 62, 709, 10.1016/j.jacc.2013.02.074
Obayashi, 2011, Cerivastatin induces type-I fiber-, not type-II fiber-, predominant muscular toxicity in the young male F344 rats, J Toxicol Sci, 36, 445, 10.2131/jts.36.445
Sidaway, 2009, Statin-induced myopathy in the rat: relationship between systemic exposure, muscle exposure and myopathy, Xenobiotica, 39, 90, 10.1080/00498250802585539
Madsen, 2008, The guinea pig as a preclinical model for demonstrating the efficacy and safety of statins, J Pharmacol Exp Ther, 324, 576, 10.1124/jpet.107.131615
Naba, 2006, Improving effect of ethyl eicosapentanoate on statin-induced rhabdomyolysis in Eisai hyperbilirubinemic rats, Biochem Biophys Res Commun, 340, 215, 10.1016/j.bbrc.2005.11.179
Zhang, 2014, Lipin-1 regulates autophagy clearance and intersects with statin drug effects in skeletal muscle, Cell Metab, 20, 267, 10.1016/j.cmet.2014.05.003
Limaye, 2014, Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase in patients with immune-mediated myositis and necrotizing myopathy, Muscle Nerve
Knauer, 2010, Human skeletal muscle drug transporters determine local exposure and toxicity of statins, Circ Res, 106, 297, 10.1161/CIRCRESAHA.109.203596
Rodrigues, 2010, Efflux and uptake transporters as determinants of statin response, Expert Opin Drug Metab Toxicol, 6, 621, 10.1517/17425251003713519
Bersot, 2011, Drug therapy for hypercholesterolemia and dyslipidemia, Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th ed, 877
DeGorter, 2013, Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care, Circ Cardiovasc Genet, 6, 400, 10.1161/CIRCGENETICS.113.000099
Gong, 2013, Impact of genetic variation in OATP transporters to drug disposition and response, Drug Metab Pharmacokinet, 28, 4, 10.2133/dmpk.DMPK-12-RV-099
SEARCH Collaborative Group, 2008, SLCO1B1 variants and statin-induced myopathy--a genome wide study, N Engl J Med, 359, 789, 10.1056/NEJMoa0801936
Vladutiu, 2011, Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathies, Molec Genet Metab, 104, 167, 10.1016/j.ymgme.2011.07.001
Vladutiu, 2014, Inborn errors of muscle metabolism implicated in risk for statin-induced myopathy, Molec Genet Metab, 111, 264
Baker, 2008, Metabolic myopathies discovered during investigations of statin myopathy, Can J Neurol Sci, 35, 94, 10.1017/S0317167100007630
Ruaño, 2011, Mechanisms of statin-induced myalgia assessed by physiogenomic associations, Atherosclerosis, 218, 451, 10.1016/j.atherosclerosis.2011.07.007
Mangravite, 2013, A statin-dependent QTL for GATM expression is associated with statin-induced myopathy, Nature, 502, 377, 10.1038/nature12508
Oh, 2007, Genetic determinants of statin intolerance, Lipids Health Dis, 6, 7, 10.1186/1476-511X-6-7
De Vera, 2014, Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review, Br J Clin Pharmacol, 78, 684, 10.1111/bcp.12339
Fleisher, 2007, ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery), Circulation, 116, 1971, 10.1161/CIRCULATIONAHA.107.185700